Scientists at The University of Nottingham have discovered a new molecule that could offer the hope of new treatments for people allergic to the house dust mite. The molecule, DC-SIGN, can be found on the surface of the immune cells which play a key role in the recognition of a major allergen from house dust mites called Der p 1, a leading cause of asthma.
Cyanide poisoning is often fatal and typically affects victims of industrial accidents, terrorist attacks, or structural fires. Based on research conducted at the Center for Drug Design at the University of Minnesota, startup Vytacera Pharma Inc. will develop and market Sulfanegen, a treatment for cyanide poisoning.
University of Texas, Arlington engineers working with Army surgeons are developing a pliable, polymer mask embedded with electrical, mechanical, and biological components that can speed healing from disfiguring facial burns and help rebuild the faces of injured soldiers.
A receptor found on blood platelets whose importance as a potential pharmaceutical target has long been questioned may in fact be fruitful in drug testing, according to new research from Michigan State University chemists.
Modified probiotics, the beneficial bacteria touted for their role in digestive health, could one day decrease the risk of Listeria infection in people with susceptible immune systems, according to Purdue University research.
New research demonstrates that previous models used to examine cancer may not be complex enough to accurately mimic the true cancer environment. Using oral cancer cells in a 3D model of lab-made tissue that mimics the lining of the oral cavity, the researchers found that the tissue surrounding cancer cells can epigenetically mediate, or temporarily trigger, the expression or suppression of a cell adhesion protein associated with the progression of cancer.
Ariel Pharmaceuticals, a private, development-stage pharmaceutical company focused on the development and commercialization of products for indications in acute central nervous system diseases and trauma, announced it has signed a cooperative research and development agreement (CRADA) with the United States Army Medical Research and Material Command.
Two related studies from Northwestern University offer new strategies for tackling the challenges of preventing and treating diseases of protein folding. The research identified new genes and pathways that prevent protein misfolding and toxic aggregation, keeping cells healthy, and also identified small molecules with therapeutic potential that restore health to damaged cells, providing new targets for drug development.
Testing the effectiveness of new pharmaceuticals may get faster thanks to a new technique incorporating quantum dots developed at the University of Central Florida (UCF). Some drug testing can take a decade or more, but a UCF team has created an electronic quantum dots (Qdots) probe that "lights up" when a drug it is delivering attaches to cancer cells.
Scientists at Purdue University and eight other institutions have developed new resources poised to unlock another door in the hidden garden of medicinally important compounds found in plants.
JM ?Science’s AQV-2200S AQUACOUNTER Karl Fischer Volumetric Titrator features small volume titration cells requiring only 20 mL of titration solvent for accurate measurements. The instrument is suitable for a wide measurement range from 100 ppm to 100% water content.
The promise of stem cell research for drug discovery and cell-based therapies depends on the ability of scientists to acquire stem cell lines for their research. A survey of more than 200 human embryonic stem cell researchers in the United States found that nearly four in ten researchers have faced excessive delay in acquiring a human embryonic stem cell line and that more than one-quarter were unable to acquire a line they wanted to study.
Over the past year, researchers at the California Institute of Technology (Caltech), and around the world, have been studying a group of potent antibodies that have the ability to neutralize HIV in the laboratory; their hope is that they may learn how to create a vaccine that makes antibodies with similar properties. Now, biologists at Caltech have taken one step closer to that goal: They have developed a way to deliver these antibodies to mice and, in so doing, have effectively protected them from HIV infection.
Chemists at Brown University have synthesized a new compound that makes drug-resistant bacteria susceptible again to antibiotics. The compound—BU-005—blocks pumps that a bacterium employs to expel an antibacterial agent called chloramphenicol. The team used a new and highly efficient method for the synthesis of BU-005 and other C-capped dipeptides.
A research team headed by the Georgia Institute of Technology has developed a computer program that can study larger molecules (more than 200 atoms) faster than any other program in existence, helping in pursuit of creating new pharmaceuticals.
The company behind a pioneering stem cell bandage, believed to be the world's first adult and autologous (patient's own) stem cell treatment designed to heal torn meniscal cartilage, can now take the technology to human clinical trials thanks to an investment from one of the U.K.'s most successful entrepreneurs.
The family of complex compounds known as taxanes are exceedingly difficult to produce in the lab, limiting the use of Taxol, an important cancer drug, and hindering the discovery of related taxadienes. Scripps Research Institute scientists have found a way to simplify this process, potentially opening up new drug leads.
Researchers at the University of Copenhagen are behind the development of a new method that will make it possible to develop drugs faster and greener. This will lead to cheaper medicine for consumers.
Sanford-Burnham Medical Research Institute has partnered with Pfizer Inc. as part of Pfizer's commitment to transforming research and development through a focus on translational medicine.
A new partnership between North Carolina State University and Wake Forest Baptist Medical Center will make regenerative medical treatments more quickly available to both human and animal patients.
Using highly potent antibodies isolated from HIV-positive people, researchers have recently begun to identify ways to broadly neutralize the many possible subtypes of HIV. Now, a team led by biologists at the California Institute of Technology has built upon one of these naturally occurring antibodies to create a stronger version they believe is a better candidate for clinical applications.
Among the complex molecular processes involved in the development of bacteria-borne disease is quorum sensing, the way bacteria communicate and coordinate collective behaviors. By studying how to inhibit quorum sensing, scientists may be able create antibacterial pharmaceuticals for a variety of ailments.
A team of researchers at the Massachusetts Institute of Technology has developed a new technology that can measure multiple aspects of individual T cells' responses to HIV-infected cells, including their ability to kill them. The technology could make it easier to monitor and design vaccines against HIV.
Data from a clinical trial involving University of California, Los Angeles researchers suggest that a new therapy may potentially serve as a "functional cure" for HIV/AIDS. The therapy, called SB-728-T, involves the modification of both copies of a patient's CCR5 gene, which encodes the major co-receptor used by HIV to infect immune system cells.
Purdue University is part of a national institute that received a grant of up to $35 million over the next five years from the U.S. Food and Drug Administration (FDA). The FDA awarded the grant to the National Institute for Pharmaceutical Technology and Education, or NIPTE, to improve manufacturing standards and ultimately cut health care costs, create jobs, and improve drug safety.